How to Use Saxenda: Injection & Safety Guide

How to use Saxenda correctly is essential knowledge for anyone starting liraglutide treatment for weight management. Saxenda (liraglutide 6 mg/ml) is a once-daily subcutaneous injection administered via a pre-filled pen, and using it safely requires understanding the correct injection technique, dose escalation schedule, storage requirements, and what to do if a dose is missed. This guide covers everything you need to know, from priming the pen for the first time to understanding side effects, eligibility criteria, and when to seek medical advice.

How do you inject Saxenda correctly for the first time?

Prime the pen before first use by attaching a new needle and pressing the dose button until a drop appears at the tip, then inject subcutaneously at a 90-degree angle into the abdomen, thigh, or upper arm, holding the button for at least six seconds.

To inject Saxenda correctly for the first time, you must prime the pen before use, choose an appropriate injection site, and follow the step-by-step instructions in the patient information leaflet. Saxenda (liraglutide 6 mg/ml) is a pre-filled, multi-dose pen that delivers a subcutaneous injection once daily, regardless of mealtimes.^[1][2]

Before your first injection, prime the pen by attaching a new needle, turning the dose selector to the flow check symbol, and pressing the dose button until a drop of solution appears at the needle tip. This confirms the pen is working correctly and removes air from the cartridge. Always check the priming steps against the Instructions for Use supplied with your pen, as these give the authoritative device-specific guidance.

For the injection itself:

• Suitable sites include the abdomen, upper thigh, or upper arm

• Rotate injection sites with each dose to reduce the risk of skin reactions such as lipodystrophy

• Insert the needle at a 90-degree angle; pinching the skin may or may not be needed depending on needle length and your body composition, so follow the guidance in your Instructions for Use

• Press the dose button fully and hold it down for at least six seconds to ensure the full dose is delivered

• Check the dose counter has returned to zero before withdrawing the needle

• After injecting, place the outer needle cap back on the needle, unscrew the capped needle, and dispose of it immediately in a sharps bin. Do not reuse needles

Always use a new, sterile needle for every injection. Never share your pen with another person, even if the needle is changed, as this carries a risk of cross-infection. If you are unsure about the injection technique, ask your pharmacist or diabetes nurse to demonstrate it before you begin. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a clinician can guide you through appropriate treatment options.

What should you do if you miss a Saxenda dose?

Inject the missed dose as soon as you remember, provided the next scheduled dose is at least 12 hours away; if not, skip it and resume your normal schedule the following day.

If you miss a Saxenda dose, you should inject it as soon as you remember, provided your next scheduled dose is at least 12 hours away.^[3][2] Saxenda is taken once daily, and maintaining a consistent daily routine helps to keep liraglutide levels stable in the body, which supports its appetite-regulating effect.

Liraglutide works as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the action of the naturally occurring hormone GLP-1 to reduce appetite and slow gastric emptying. Because of its pharmacokinetic profile, missing a single dose is unlikely to cause a significant gap in effect, but consistency over time is important for achieving the best outcomes.

If fewer than 12 hours remain before your next dose is due, skip the missed dose entirely and resume your normal schedule the following day. Do not take two doses on the same day or within 12 hours of each other, as this increases the risk of side effects such as nausea and vomiting without providing additional benefit.

If you miss more than three consecutive days of Saxenda, contact your prescriber or pharmacist before restarting. Re-starting at a lower dose and re-escalating gradually may be recommended to minimise gastrointestinal side effects; your prescriber or pharmacist can advise on the appropriate restart regimen based on the current PIL and SmPC guidance. Keep a note of any missed doses to discuss at your next review appointment, as persistent missed doses may affect your overall progress and the clinical decision about whether to continue treatment.

Side effects of Saxenda: what to expect and when to get help

The most common side effects are gastrointestinal, including nausea and vomiting, and typically improve as the body adjusts; severe persistent abdominal pain may indicate pancreatitis and requires prompt medical attention.

The most common side effects of Saxenda are gastrointestinal in nature, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, and these are most likely to occur during the dose escalation phase. These effects typically improve as the body adjusts to the medication over several weeks.

Saxenda is started at 0.6 mg daily and increased in weekly increments up to the maintenance dose of 3.0 mg daily. This gradual escalation is specifically designed to reduce the severity of gastrointestinal side effects. Eating smaller meals, avoiding high-fat foods, and staying well hydrated can help manage nausea during this period.

Other reported side effects include:

• Injection site reactions such as redness, bruising, or itching

• Headache and dizziness, particularly in the early weeks

• Low blood sugar (hypoglycaemia), most likely if Saxenda is used alongside insulin, sulfonylureas, or other glucose-lowering medicines; people without diabetes using Saxenda alone are at lower risk^[1][2]

• Increased heart rate, which should be reported to your GP if persistent

• Gallbladder problems, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis); seek medical advice promptly if you develop persistent pain in the upper right abdomen, fever, or yellowing of the skin or eyes

Acute pancreatitis has been reported in association with liraglutide, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[1][11] If you develop severe and persistent abdominal pain, particularly pain that radiates to the back, stop taking Saxenda and contact your GP promptly. If symptoms are severe, attend A&E.

If vomiting or diarrhoea is prolonged, ensure you maintain adequate fluid intake, as dehydration can affect kidney function. Seek medical advice if you are unable to keep fluids down.

Pregnancy, breastfeeding and contraception: Saxenda is not recommended during pregnancy or breastfeeding.^[1][2] If you become pregnant while using Saxenda, stop treatment and contact your prescriber promptly. Use effective contraception while taking Saxenda; discuss suitable options with your prescriber or pharmacist before starting treatment.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you experience signs of a serious allergic reaction, including swelling of the face, lips, or throat, or difficulty breathing, call 999 immediately. For non-urgent concerns about side effects, contact your GP or call NHS 111 for advice.

How to store your Saxenda pen and keep it working properly

Unopened pens must be refrigerated at 2°C to 8°C and never frozen; once in use, pens can be kept below 30°C for up to 30 days, after which they must be discarded.

Saxenda pens that have not yet been opened must be stored in a refrigerator at 2°C to 8°C, away from the freezer compartment, and should never be frozen. Freezing renders the solution unusable, and a pen that has been frozen must be discarded even if it appears unchanged.

Once a Saxenda pen is in use, it can be kept at room temperature (below 30°C) or in the refrigerator for up to 30 days. After 30 days, the pen must be discarded regardless of how much solution remains. Always check the expiry date printed on the pen label and do not use the pen beyond that date. Keep Saxenda out of the sight and reach of children.

To keep your pen working correctly:

• Remove the needle after every injection and store the pen without a needle attached to prevent air entering the cartridge and to reduce the risk of leakage or blockage

• Keep the pen cap on when not in use to protect the cartridge from light

• Do not expose the pen to direct sunlight or sources of heat such as radiators or car dashboards

• Inspect the solution before each injection: it should be clear, colourless, and free from particles. Do not use the pen if the solution appears cloudy, discoloured, or contains visible particles, or if the pen appears damaged

Used needles must be disposed of safely in an approved sharps container. Your local council, GP surgery, or community pharmacy can advise on sharps disposal services in your area. Never place loose needles in household waste or recycling bins.

Who can use Saxenda on the NHS and what are the eligibility criteria?

NICE TA664 recommends Saxenda for adults with a BMI of 35 kg/m² or above and at least one weight-related comorbidity, accessed through specialist tier 3 or tier 4 weight management services.

Saxenda is available on the NHS for adults with obesity, but access is limited to specialist weight management services and depends on local commissioning decisions made by Integrated Care Boards (ICBs). Eligibility criteria can vary across England, Scotland, Wales, and Northern Ireland. NICE technology appraisal guidance TA664 recommends liraglutide 3.0 mg (Saxenda) as an option for managing overweight and obesity in adults within specialist weight management services.

Under NICE TA664, Saxenda may be recommended for adults who meet all of the following criteria:

• BMI of 35 kg/m² or above (or lower thresholds in certain high-risk groups, including some people from Black, Asian, and minority ethnic backgrounds where adjusted BMI thresholds apply; check the current NICE TA664 guidance or ask your specialist for the precise figures applicable to you)

• At least one weight-related comorbidity, such as type 2 diabetes, hypertension, or obstructive sleep apnoea

• Referral to a specialist tier 3 or tier 4 weight management service, where Saxenda is used alongside dietary, physical activity, and behavioural support

NICE TA664 also specifies that treatment should be discontinued after 12 weeks at the maintenance dose of 3.0 mg if the person has not lost at least 5% of their initial body weight, as this suggests an insufficient response. You should discuss with your specialist whether any maximum treatment duration applies in your case, as guidance and local commissioning policies may specify limits.

Saxenda is initiated within specialist services and is not routinely prescribed in primary care.^[7][8] If you live in Scotland, Wales, or Northern Ireland, local guidance from the Scottish Medicines Consortium, the All Wales Therapeutics and Toxicology Centre, or the Department of Health Northern Ireland may apply, and arrangements can differ from those in England.

For those who do not meet NHS criteria or who are seeking treatment outside a specialist service, Saxenda may be available privately following a clinical assessment. Eligibility, prescribing decisions, and ongoing monitoring requirements should always be discussed with a qualified prescriber. Your GP is the most appropriate first point of contact to discuss NHS referral pathways and whether Saxenda is suitable for your individual circumstances.

Scientific References

1. Saxenda 6 mg/mL solution for injection in pre-filled pen – Summary of Product Characteristics.
2. Saxenda 6 mg/mL solution for injection in pre-filled pen – Patient Information Leaflet.
3. Saxenda Patient Information Leaflet (PDF).
4. Saxenda, INN-liraglutide – EPAR Product Information.
5. Saxenda | European Medicines Agency.
6. Liraglutide: a medicine to treat type 2 diabetes or obesity.
7. Liraglutide for managing overweight and obesity (TA664) – Recommendations.
8. Liraglutide for managing overweight and obesity (TA664) – Full guidance PDF.
9. Liraglutide for managing overweight and obesity (TA664) – Supporting document.
10. Liraglutide | Drugs | BNF – NICE.
11. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
12. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
13. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
14. Combination pharmacotherapy with incretins: what works best and when?.
15. Potential side effects to GLP-1 agonists: understanding their safety and tolerability.
16. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
17. Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes.
18. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.

Frequently Asked Questions